3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Dermatologic
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
13
Gastrointestinal Stromal Tumors
12
Leukemia, Myeloid, Chronic-Phase
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Leukemia
3
Neoplasms
2
Melanoma
2
Burkitt Lymphoma
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Thyroid Cancer, Papillary
1
Squamous Cell Carcinoma of Head and Neck
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
1
Philadelphia Chromosome
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Lymphangioleiomyomatosis
1
Leukemia, Myeloid
1
Leukemia, Biphenotypic, Acute
1
Hypereosinophilic Syndrome
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Graft vs Host Disease
1
Digestive System Neoplasms
1
Desmoid Tumors
1
Dermatofibrosarcoma
1
Congenital Bone Marrow Failure Syndromes
1
Chordoma
1
Carcinoma, Adenoid Cystic
1
Interventions
pembrolizumab
4
lenvatinib
3
Magnetic Resonance Spectroscopy
3
Specimen Handling
2
Nivolumab
2
Epirubicin
2
regorafenib
1
gallium 68 PSMA-11
1
enfortumab vedotin
1
anlotinib
1
amivantamab
1
abemaciclib
1
Tablets
1
Surveys and Questionnaires
1
Standard of Care
1
Radiosurgery
1
Pemetrexed
1
Observation
1
Ipilimumab
1
Imatinib Mesylate
1
Glutamate Carboxypeptidase II
1
Cyclophosphamide
1
Combined Modality Therapy
1
Carboplatin
1
CTLA-4 Antigen
1
Blood Specimen Collection
1
BMS-906024
1
68Ga-DKFZ-PSMA-11
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Adenoid Cystic
×
Imatinib Mesylate
×
1 year
×
Clear all
NCT01046487
2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1
Completed
26 enrolled